Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: A pilot study

Z. Harel, K. Wolter, M. A. Gold, B. Cromer, A. Bruner, M. Stager, L. Bachrach, P. Hertweck, A. Nelson, D. Nelson, Susan M. Coupey, C. C. Johnson, R. Burkman, H. Bone

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Study Objective: To examine vitamin D and parathormone (PTH) levels in adolescents who experienced substantial bone mineral density (BMD) loss during depot medroxyprogesterone acetate (DMPA) use. Design: A non-randomized, multi-center study, during which DMPA was administered every 12 weeks and evaluation of lumbar spine and hip BMD by dual-energy X-ray absorptiometry (DXA) was conducted every 6 months. A blood sample for vitamin D and PTH measurements was obtained from adolescents who experienced >5% BMD loss. Vitamin D deficiency was defined as 25-hydroxyvitamin D (25OHD) level of <20ng/mL, insufficiency as 25OHD level of 20-30ng/mL, and sufficiency as 25OHD level of >30ng/mL. Results: Evaluation of vitamin D and PTH was carried out in 15 participants who experienced BMD loss of ≥5% during DMPA use. At initiation of DMPA, participants had mean (+SE) age 17+1years, gynecologic age 61+4 months, and body mass index 24+1.5kg/m2. Racial/ethnic distribution was: Caucasian-7 girls, Hispanic-4 girls, African-American-3 girls, and other-1 girl. Six participants had BMD loss of >5% after 2 DMPA injections, five after 3 injections, one after 5 injections, one after 8 injections, one after 10 injections, and one after 13 injections. Only one girl (7%) had sufficient vitamin D. The other participants had vitamin D insufficiency (50%) or deficiency (43%). Participants' mean (+SE) PTH was 22+4pg/mL (reference range 7-53pg/mL), and mean (+SE) 1,25-dihydroxyvitamin D was 56+5pg/mL (reference range 22-67pg/mL). Conclusions: Inadequate vitamin D status was evident among the majority of female adolescents who experienced a substantial BMD loss while using DMPA.

Original languageEnglish (US)
Pages (from-to)209-214
Number of pages6
JournalJournal of Pediatric and Adolescent Gynecology
Volume23
Issue number4
DOIs
StatePublished - Aug 2010

Fingerprint

Medroxyprogesterone Acetate
Contraceptive Agents
Vitamin D
Bone Density
Parathyroid Hormone
Injections
Reference Values
Pelvic Bones
Vitamin D Deficiency
Photon Absorptiometry
Hispanic Americans
African Americans
Spine
Body Mass Index

Keywords

  • Adolescents
  • Bone mineral density
  • Female
  • Med roxyprogesterone acetate (DMPA, Depo-Provera)
  • Vitamin D

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)

Cite this

Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive : A pilot study. / Harel, Z.; Wolter, K.; Gold, M. A.; Cromer, B.; Bruner, A.; Stager, M.; Bachrach, L.; Hertweck, P.; Nelson, A.; Nelson, D.; Coupey, Susan M.; Johnson, C. C.; Burkman, R.; Bone, H.

In: Journal of Pediatric and Adolescent Gynecology, Vol. 23, No. 4, 08.2010, p. 209-214.

Research output: Contribution to journalArticle

Harel, Z, Wolter, K, Gold, MA, Cromer, B, Bruner, A, Stager, M, Bachrach, L, Hertweck, P, Nelson, A, Nelson, D, Coupey, SM, Johnson, CC, Burkman, R & Bone, H 2010, 'Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: A pilot study', Journal of Pediatric and Adolescent Gynecology, vol. 23, no. 4, pp. 209-214. https://doi.org/10.1016/j.jpag.2009.11.004
Harel, Z. ; Wolter, K. ; Gold, M. A. ; Cromer, B. ; Bruner, A. ; Stager, M. ; Bachrach, L. ; Hertweck, P. ; Nelson, A. ; Nelson, D. ; Coupey, Susan M. ; Johnson, C. C. ; Burkman, R. ; Bone, H. / Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive : A pilot study. In: Journal of Pediatric and Adolescent Gynecology. 2010 ; Vol. 23, No. 4. pp. 209-214.
@article{f92791829e0f421cb0a16af04f6d5c04,
title = "Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: A pilot study",
abstract = "Study Objective: To examine vitamin D and parathormone (PTH) levels in adolescents who experienced substantial bone mineral density (BMD) loss during depot medroxyprogesterone acetate (DMPA) use. Design: A non-randomized, multi-center study, during which DMPA was administered every 12 weeks and evaluation of lumbar spine and hip BMD by dual-energy X-ray absorptiometry (DXA) was conducted every 6 months. A blood sample for vitamin D and PTH measurements was obtained from adolescents who experienced >5{\%} BMD loss. Vitamin D deficiency was defined as 25-hydroxyvitamin D (25OHD) level of <20ng/mL, insufficiency as 25OHD level of 20-30ng/mL, and sufficiency as 25OHD level of >30ng/mL. Results: Evaluation of vitamin D and PTH was carried out in 15 participants who experienced BMD loss of ≥5{\%} during DMPA use. At initiation of DMPA, participants had mean (+SE) age 17+1years, gynecologic age 61+4 months, and body mass index 24+1.5kg/m2. Racial/ethnic distribution was: Caucasian-7 girls, Hispanic-4 girls, African-American-3 girls, and other-1 girl. Six participants had BMD loss of >5{\%} after 2 DMPA injections, five after 3 injections, one after 5 injections, one after 8 injections, one after 10 injections, and one after 13 injections. Only one girl (7{\%}) had sufficient vitamin D. The other participants had vitamin D insufficiency (50{\%}) or deficiency (43{\%}). Participants' mean (+SE) PTH was 22+4pg/mL (reference range 7-53pg/mL), and mean (+SE) 1,25-dihydroxyvitamin D was 56+5pg/mL (reference range 22-67pg/mL). Conclusions: Inadequate vitamin D status was evident among the majority of female adolescents who experienced a substantial BMD loss while using DMPA.",
keywords = "Adolescents, Bone mineral density, Female, Med roxyprogesterone acetate (DMPA, Depo-Provera), Vitamin D",
author = "Z. Harel and K. Wolter and Gold, {M. A.} and B. Cromer and A. Bruner and M. Stager and L. Bachrach and P. Hertweck and A. Nelson and D. Nelson and Coupey, {Susan M.} and Johnson, {C. C.} and R. Burkman and H. Bone",
year = "2010",
month = "8",
doi = "10.1016/j.jpag.2009.11.004",
language = "English (US)",
volume = "23",
pages = "209--214",
journal = "Journal of Pediatric and Adolescent Gynecology",
issn = "1083-3188",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive

T2 - A pilot study

AU - Harel, Z.

AU - Wolter, K.

AU - Gold, M. A.

AU - Cromer, B.

AU - Bruner, A.

AU - Stager, M.

AU - Bachrach, L.

AU - Hertweck, P.

AU - Nelson, A.

AU - Nelson, D.

AU - Coupey, Susan M.

AU - Johnson, C. C.

AU - Burkman, R.

AU - Bone, H.

PY - 2010/8

Y1 - 2010/8

N2 - Study Objective: To examine vitamin D and parathormone (PTH) levels in adolescents who experienced substantial bone mineral density (BMD) loss during depot medroxyprogesterone acetate (DMPA) use. Design: A non-randomized, multi-center study, during which DMPA was administered every 12 weeks and evaluation of lumbar spine and hip BMD by dual-energy X-ray absorptiometry (DXA) was conducted every 6 months. A blood sample for vitamin D and PTH measurements was obtained from adolescents who experienced >5% BMD loss. Vitamin D deficiency was defined as 25-hydroxyvitamin D (25OHD) level of <20ng/mL, insufficiency as 25OHD level of 20-30ng/mL, and sufficiency as 25OHD level of >30ng/mL. Results: Evaluation of vitamin D and PTH was carried out in 15 participants who experienced BMD loss of ≥5% during DMPA use. At initiation of DMPA, participants had mean (+SE) age 17+1years, gynecologic age 61+4 months, and body mass index 24+1.5kg/m2. Racial/ethnic distribution was: Caucasian-7 girls, Hispanic-4 girls, African-American-3 girls, and other-1 girl. Six participants had BMD loss of >5% after 2 DMPA injections, five after 3 injections, one after 5 injections, one after 8 injections, one after 10 injections, and one after 13 injections. Only one girl (7%) had sufficient vitamin D. The other participants had vitamin D insufficiency (50%) or deficiency (43%). Participants' mean (+SE) PTH was 22+4pg/mL (reference range 7-53pg/mL), and mean (+SE) 1,25-dihydroxyvitamin D was 56+5pg/mL (reference range 22-67pg/mL). Conclusions: Inadequate vitamin D status was evident among the majority of female adolescents who experienced a substantial BMD loss while using DMPA.

AB - Study Objective: To examine vitamin D and parathormone (PTH) levels in adolescents who experienced substantial bone mineral density (BMD) loss during depot medroxyprogesterone acetate (DMPA) use. Design: A non-randomized, multi-center study, during which DMPA was administered every 12 weeks and evaluation of lumbar spine and hip BMD by dual-energy X-ray absorptiometry (DXA) was conducted every 6 months. A blood sample for vitamin D and PTH measurements was obtained from adolescents who experienced >5% BMD loss. Vitamin D deficiency was defined as 25-hydroxyvitamin D (25OHD) level of <20ng/mL, insufficiency as 25OHD level of 20-30ng/mL, and sufficiency as 25OHD level of >30ng/mL. Results: Evaluation of vitamin D and PTH was carried out in 15 participants who experienced BMD loss of ≥5% during DMPA use. At initiation of DMPA, participants had mean (+SE) age 17+1years, gynecologic age 61+4 months, and body mass index 24+1.5kg/m2. Racial/ethnic distribution was: Caucasian-7 girls, Hispanic-4 girls, African-American-3 girls, and other-1 girl. Six participants had BMD loss of >5% after 2 DMPA injections, five after 3 injections, one after 5 injections, one after 8 injections, one after 10 injections, and one after 13 injections. Only one girl (7%) had sufficient vitamin D. The other participants had vitamin D insufficiency (50%) or deficiency (43%). Participants' mean (+SE) PTH was 22+4pg/mL (reference range 7-53pg/mL), and mean (+SE) 1,25-dihydroxyvitamin D was 56+5pg/mL (reference range 22-67pg/mL). Conclusions: Inadequate vitamin D status was evident among the majority of female adolescents who experienced a substantial BMD loss while using DMPA.

KW - Adolescents

KW - Bone mineral density

KW - Female

KW - Med roxyprogesterone acetate (DMPA, Depo-Provera)

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=77954027251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954027251&partnerID=8YFLogxK

U2 - 10.1016/j.jpag.2009.11.004

DO - 10.1016/j.jpag.2009.11.004

M3 - Article

C2 - 20471875

AN - SCOPUS:77954027251

VL - 23

SP - 209

EP - 214

JO - Journal of Pediatric and Adolescent Gynecology

JF - Journal of Pediatric and Adolescent Gynecology

SN - 1083-3188

IS - 4

ER -